Skip to main content
Premium Trial:

Request an Annual Quote

Seer Closes $55M Series D Financing Round

NEW YORK — Proteomics firm Seer said today that it has closed a $55 million Series D funding round.

The company plans to use the funds to develop and commercialize its Proteograph proteomics platform for research and clinical applications. According to the company the platform allows for proteomics at a scale and speed not possible with existing platforms.

The round was led by life science venture capital fund aMoon with participation from existing and other new investors.

"We are impressed with the Seer team’s approach and progress, and we are very enthusiastic about the potential for the company's platform to meet the research and clinical need to accurately capture proteomic data at an unprecedented speed and scale," Tomer Berkovitz, partner and CFO at aMoon, said in a statement.

"Undoubtedly, large-scale proteomics has the potential to make scientific, clinical, and market impact at the same or higher levels than genomics has made over the past decade," said Omid Farokhzad, Seer's founder and CEO. "We believe our proprietary technology, multifaceted product strategy, and exceptional team well position Seer to be a leader in the proteomics space."